Trial intelligence / Profile preview

Phase 3 randomized double-blind placebo-controlled study of inhaled bromhexine hydrochloride solution for sticky sputum symptoms in lower respiratory tract infectious diseases

CTR20222181Phase 3Completed

Sponsor
Yiyou Pharmaceutical
Start
Nov 2022
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial in pulmonary infection, acute bronchitis, chronic bronchitis (CB) and 2 more comparing Inhaled bromhexine hydrochloride solution with Placebo (2 arms). Primary endpoint: Change from baseline in sputum character score after completion of treatment. Started Nov 2022; status: completed.

02

Drugs

bromhexine
03

Conditions

pulmonary infectionacute bronchitischronic bronchitis (CB)pulmonary tuberculosis (TB)pneumoconiosis

Beyond the preview

Go deeper on CTR20222181.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20222181.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call